| |  Online-Ressource |
|---|
| Verfasst von: | Novello, Silvia [VerfasserIn]  |
|---|
| | Torri, V. [VerfasserIn] |
|---|
| | Grohé, Christian [VerfasserIn] |
|---|
| | Kurz, S. [VerfasserIn] |
|---|
| | Serke, M. [VerfasserIn] |
|---|
| | Wehler, T. [VerfasserIn] |
|---|
| | Meyer, A. [VerfasserIn] |
|---|
| | Ladage, D. [VerfasserIn] |
|---|
| | Geissler, M. [VerfasserIn] |
|---|
| | Colantonio, I. [VerfasserIn] |
|---|
| | Cauchi, C. [VerfasserIn] |
|---|
| | Stoelben, E. [VerfasserIn] |
|---|
| | Ceribelli, A. [VerfasserIn] |
|---|
| | Kropf-Sanchen, C. [VerfasserIn] |
|---|
| | Valmadre, G. [VerfasserIn] |
|---|
| | Borra, G. [VerfasserIn] |
|---|
| | Schena, M. [VerfasserIn] |
|---|
| | Morabito, A. [VerfasserIn] |
|---|
| | Santo, A. [VerfasserIn] |
|---|
| | Gregorc, V. [VerfasserIn] |
|---|
| | Chiari, R. [VerfasserIn] |
|---|
| | Reck, M. [VerfasserIn] |
|---|
| | Schmid-Bindert, Gerald [VerfasserIn] |
|---|
| | Folprecht, G. [VerfasserIn] |
|---|
| | Griesinger, Frank [VerfasserIn] |
|---|
| | Follador, A. [VerfasserIn] |
|---|
| | Pedrazzoli, P. [VerfasserIn] |
|---|
| | Bearz, A. [VerfasserIn] |
|---|
| | Caffo, O. [VerfasserIn] |
|---|
| | Dickgreber, N. J. [VerfasserIn] |
|---|
| | Irtelli, L. [VerfasserIn] |
|---|
| | Wiest, G. [VerfasserIn] |
|---|
| | Monica, V. [VerfasserIn] |
|---|
| | Porcu, L. [VerfasserIn] |
|---|
| | Manegold, Christian [VerfasserIn] |
|---|
| | Scagliotti, G. V. [VerfasserIn] |
|---|
| Titel: | International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer |
|---|
| Verf.angabe: | S. Novello, V. Torri, C. Grohe, S. Kurz, M. Serke, T. Wehler, A. Meyer, D. Ladage, M. Geissler, I. Colantonio, C. Cauchi, E. Stoelben, A. Ceribelli, C. Kropf-Sanchen, G. Valmadre, G. Borra, M. Schena, A. Morabito, A. Santo, V. Gregorc, R. Chiari, M. Reck, G. Schmid-Bindert, G. Folprecht, F. Griesinger, A. Follador, P. Pedrazzoli, A. Bearz, O. Caffo, N.J. Dickgreber, L. Irtelli, G. Wiest, V. Monica, L. Porcu, C. Manegold and G.V. Scagliotti |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | January 2022 |
|---|
| Umfang: | 10 S. |
|---|
| Fussnoten: | Online verfügbar: 5. Oktober 2021, Artikelversion: 16. Dezember 2021 ; Gesehen am 20.08.2024 |
|---|
| Titel Quelle: | Enthalten in: Annals of oncology |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier, 1990 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 33(2022), 1 vom: Jan., Seite 57-66 |
|---|
| ISSN Quelle: | 1569-8041 |
|---|
| Abstract: | Background - Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small-cell lung cancer (NSCLC). In this investigator-initiated study we aimed to evaluate the predictive utility of the messenger RNA (mRNA) expression levels of excision repair cross complementation group 1 (ERCC1) and thymidylate synthase (TS) as assessed in resected tumor. - Patients and methods - Seven hundred and seventy-three completely resected stage II-III NSCLC patients were enrolled and randomly assigned in each of the four genomic subgroups to investigator’s choice of platinum-based chemotherapy (C, n = 389) or tailored chemotherapy (T, n = 384). All anticancer drugs were administered according to standard doses and schedules. Stratification factors included stage and smoking status. The primary endpoint of the study was overall survival (OS). - Results - Six hundred and ninety patients were included in the primary analysis. At a median follow-up of 45.9 months, 85 (24.6%) and 70 (20.3%) patients died in arms C and T, respectively. Five-year survival for patients in arms C and T was of 65.4% (95% CI (confidence interval): 58.5% to 71.4%) and 72.9% (95% CI: 66.5% to 78.3%), respectively. The estimated hazard ratio (HR) was 0.77 (95% CI: 0.56-1.06, P value: 0.109) for arm T versus arm C. HR for recurrence-free survival was 0.89 (95% CI: 0.69-1.14, P value: 0.341) for arm T versus arm C. Grade 3-5 toxicities were more frequently reported in arm C than in arm T. - Conclusion - In completely resected stage II-III NSCLC tailoring adjuvant chemotherapy conferred a non-statistically significant trend for OS favoring the T arm. In terms of safety, the T arm was associated with better efficacy/toxicity ratio related to the different therapeutic choices in the experimental arm. |
|---|
| DOI: | doi:10.1016/j.annonc.2021.09.017 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1016/j.annonc.2021.09.017 |
|---|
| | kostenfrei: Volltext: https://www.sciencedirect.com/science/article/pii/S0923753421044963 |
|---|
| | DOI: https://doi.org/10.1016/j.annonc.2021.09.017 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Bibliogr. Hinweis: | Errata: Novello, Silvia: Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer” |
|---|
| Sach-SW: | adjuvant chemotherapy |
|---|
| | excision repair cross-complementation 1 |
|---|
| | messenger RNA |
|---|
| | non-small-cell lung cancer |
|---|
| | pharmacogenomics |
|---|
| | thymidylate synthase |
|---|
| K10plus-PPN: | 1841086320 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer / Novello, Silvia [VerfasserIn]; January 2022 (Online-Ressource)
Andere Auflagen/Ausgaben